Browsing: Novo Nordisk
Merck Deal Boosts Founder Of Little-Known Korean Biotech Company Into Billionaire Ranks
Amid a frenzy for AI-related stocks, shares of a little-known biotech company in South Korea got an Nvidia-esque boost. Alteogen,…
Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out-of-pocket for them
The popularity of Novo Nordisk’s weight-loss drugs has been unprecedented and has shown no signs of fading. It’s clearly more…
Novo Nordisk hits $500bn market value, climbing closer to the $1tn club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Novo Nordisk has shown few signs of slowing down since taking the pharmaceutical world by storm last year. Now, the…
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
North Carolina is cutting off coverage of anti-obesity medications for state employees, citing soaring costs and a lack of agreement…
Shares of Korea-listed Caregen surged on hope its diabetes-weight loss supplement could give the little-known biotech company an Ozempic-like boost.…
Millions of people inject the new “miraculous” weight loss drugs targeting Glucagon-like peptide-1 (GLP-1) such as Wegovy, Ozempic, and Mounjaro.…